Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73

Breast Cancer Research and Treatment

Volumn 128, Issue 2, 2011, Pages 301-313

  Wong, Su Wei ^a   Tiong, Kai Hung ^a   Kong, Weng Yip ^a   Yue, Yuen Chee ^a   Chua, Choon Hooi ^a   Lim, Jae Ying ^a   Lee, Chai Yuin ^a   Quah, Sean I ^a   Fow, Cindy ^a   Chung, Cyril ^a   So, Irene ^a   Tan, Boon Shing ^a   Choo, Heng Lungh ^a   Rosli, Rozita ^b   Cheong, Soon Keng ^c   Leong, Chee Onn ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^c UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

Author keywords

Basal like breast cancer; Cisplatin; p73; Rapamycin; Synergism

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; [3 (PYRIDIN 2 YL) 4 (4 QUINONYL)] 1H PYRAZOLE; ANTINEOPLASTIC AGENT; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LY 364947; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P73; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA-BINDING PROTEINS; DRUG SYNERGISM; HUMANS; NF-KAPPA B; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 79959706655     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1055-0     Document Type: Article

References (49)

1. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein P Eystein Lonning AL Borresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 10.1073/pnas.191367098 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
2. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler J Demeter CM Perou PE Lonning PO Brown AL Borresen-Dale D Botstein 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 14 8418 8423 10.1073/pnas.0932692100 12829800 10.1073/pnas.0932692100 1:CAS:528: DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
3. CO Leong N Vidnovic MP DeYoung D Sgroi LW Ellisen 2007 The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J Clin Invest 117 5 1370 1380 10.1172/JCI30866 17446929 10.1172/JCI30866 1:CAS:528:DC%2BD2sXlt1Omtb4%3D (Pubitemid 46718425)
4. LY Lim N Vidnovic LW Ellisen CO Leong 2009 Mutant p53 mediates survival of breast cancer cells Br J Cancer 101 9 1606 1612 10.1038/sj.bjc.6605335 19773755 10.1038/sj.bjc.6605335 1:CAS:528:DC%2BD1MXhtlWlsr%2FM
5. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer N Engl J Med 353 16 1659 1672 10.1056/NEJMoa052306 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
6. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr. NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer N Engl J Med 353 16 1673 1684 10.1056/NEJMoa052122 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
7. SR Lakhani JS Reis-Filho L Fulford F Penault-Llorca M van der Vijver S Parry T Bishop J Benitez C Rivas YJ Bignon J Chang-Claude U Hamann CJ Cornelisse P Devilee MW Beckmann C Nestle-Kramling PA Daly N Haites J Varley F Lalloo G Evans C Maugard H Meijers-Heijboer JG Klijn E Olah BA Gusterson S Pilotti P Radice S Scherneck H Sobol J Jacquemier T Wagner J Peto MR Stratton L McGuffog DF Easton 2005 Prediction of brca1 status in patients with breast cancer using estrogen receptor and basal phenotype Clin Cancer Res 11 14 5175 5180 10.1158/1078-0432.CCR-04-2424 16033833 10.1158/1078-0432.CCR-04-2424 1:CAS:528:DC%2BD2MXmt12qtbk%3D (Pubitemid 41003703)
8. DP Silver AL Richardson AC Eklund ZC Wang Z Szallasi Q Li N Juul CO Leong D Calogrias A Buraimoh A Fatima RS Gelman PD Ryan NM Tung A De Nicolo S Ganesan A Miron C Colin DC Sgroi LW Ellisen EP Winer JE Garber 2010 Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 7 1145 1153 10.1200/JCO.2009.22.4725 20100965 10.1200/JCO.2009.22.4725 1:CAS:528:DC%2BC3cXktF2ltLk%3D
9. T Byrski T Huzarski R Dent J Gronwald D Zuziak C Cybulski J Kladny B Gorski J Lubinski SA Narod 2009 Response to neoadjuvant therapy with cisplatin in brca1-positive breast cancer patients Breast Cancer Res Treat 115 2 359 363 10.1007/s10549-008-0128-9 18649131 10.1007/s10549-008-0128-9 1:CAS:528:DC%2BD1MXmsVGjsrs%3D
10. JW Rocco CO Leong N Kuperwasser MP DeYoung LW Ellisen 2006 P63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis Cancer Cell 9 1 45 56 10.1016/j.ccr.2005.12.013 16413471 10.1016/j.ccr.2005.12. 013 1:CAS:528:DC%2BD28XosFersQ%3D%3D (Pubitemid 43069510)
11. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528: DyaL2cXktlaksLk%3D
12. RM Neve K Chin J Fridlyand J Yeh FL Baehner T Fevr L Clark N Bayani JP Coppe F Tong T Speed PT Spellman S DeVries A Lapuk NJ Wang WL Kuo JL Stilwell D Pinkel DG Albertson FM Waldman F McCormick RB Dickson MD Johnson M Lippman S Ethier A Gazdar JW Gray 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10 6 515 527 10.1016/j.ccr.2006.10.008 17157791 10.1016/j.ccr.2006.10.008 1:CAS:528:DC%2BD28XhtlCnsrbE (Pubitemid 44854747)
13. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 15 2568 2581 10.1200/JCO.2007.13.1748 18487574 10.1200/JCO.2007.13.1748
14. Z Hu C Fan DS Oh JS Marron X He BF Qaqish C Livasy LA Carey E Reynolds L Dressler A Nobel J Parker MG Ewend LR Sawyer J Wu Y Liu R Nanda M Tretiakova A Ruiz Orrico D Dreher JP Palazzo L Perreard E Nelson M Mone H Hansen M Mullins JF Quackenbush MJ Ellis OI Olopade PS Bernard CM Perou 2006 The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 96 10.1186/1471-2164-7-96 16643655 10.1186/1471-2164-7-96 (Pubitemid 43786485)
15. F Yehiely JV Moyano JR Evans TO Nielsen VL Cryns 2006 Deconstructing the molecular portrait of basal-like breast cancer Trends Mol Med 12 11 537 544 10.1016/j.molmed.2006.09.004 17011236 10.1016/j.molmed.2006.09.004 1:CAS:528:DC%2BD28XhtFert7fL (Pubitemid 44740239)
16. T Sorlie Y Wang C Xiao H Johnsen B Naume RR Samaha AL Borresen-Dale 2006 Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms BMC Genomics 7 127 10.1186/1471-2164-7-127 16729877 10.1186/1471-2164-7-127 (Pubitemid 44027496)
17. B Vogelstein KW Kinzler 2004 Cancer genes and the pathways they control Nat Med 10 8 789 799 10.1038/nm1087 15286780 10.1038/nm1087 1:CAS:528: DC%2BD2cXmtFWrt7o%3D (Pubitemid 39070849)
18. JM Rosenbluth DJ Mays MF Pino LJ Tang JA Pietenpol 2008 A gene signature-based approach identifies mtor as a regulator of p73 Mol Cell Biol 28 19 5951 5964 10.1128/MCB.00305-08 18678646 10.1128/MCB.00305-08 1:CAS:528:DC%2BD1cXhtF2gt7rP
19. JG Gong A Costanzo HQ Yang G Melino WG Kaelin Jr. M Levrero JY Wang 1999 The tyrosine kinase c-abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 399 6738 806 809 10.1038/21690 10391249 10.1038/21690 1:CAS:528:DyaK1MXksVSns7Y%3D (Pubitemid 29293179)
20. ZM Yuan H Shioya T Ishiko X Sun J Gu YY Huang H Lu S Kharbanda R Weichselbaum D Kufe 1999 P73 is regulated by tyrosine kinase c-abl in the apoptotic response to DNA damage Nature 399 6738 814 817 10.1038/21704 10391251 10.1038/21704 1:CAS:528:DyaK1MXksVSnsbs%3D (Pubitemid 29293181)
21. M Flinterman L Guelen S Ezzati-Nik R Killick G Melino K Tominaga JS Mymryk J Gaken M Tavassoli 2005 E1a activates transcription of p73 and noxa to induce apoptosis J Biol Chem 280 7 5945 5959 10.1074/jbc.M406661200 15572378 10.1074/jbc.M406661200 1:CAS:528:DC%2BD2MXhtlClt7c%3D (Pubitemid 40280079)
22. G Melino F Bernassola M Ranalli K Yee WX Zong M Corazzari RA Knight DR Green C Thompson KH Vousden 2004 P73 induces apoptosis via puma transactivation and bax mitochondrial translocation J Biol Chem 279 9 8076 8083 10.1074/jbc.M307469200 14634023 10.1074/jbc.M307469200 1:CAS:528: DC%2BD2cXhsFejtbo%3D (Pubitemid 38294697)
23. TO Nielsen FD Hsu K Jensen M Cheang G Karaca Z Hu T Hernandez-Boussard C Livasy D Cowan L Dressler LA Akslen J Ragaz AM Gown CB Gilks M van de Rijn CM Perou 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
24. NC Turner JS Reis-Filho 2006 Basal-like breast cancer and the brca1 phenotype Oncogene 25 43 5846 5853 10.1038/sj.onc.1209876 16998499 10.1038/sj.onc.1209876 1:CAS:528:DC%2BD28XhtVSgurjO (Pubitemid 44453440)
25. NC Turner JS Reis-Filho AM Russell RJ Springall K Ryder D Steele K Savage CE Gillett FC Schmitt A Ashworth AN Tutt 2007 Brca1 dysfunction in sporadic basal-like breast cancer Oncogene 26 14 2126 2132 10.1038/sj.onc.1210014 17016441 10.1038/sj.onc.1210014 1:CAS:528:DC%2BD2sXjsFSiu7c%3D (Pubitemid 46514749)
26. S Ganesan DP Silver RA Greenberg D Avni R Drapkin A Miron SC Mok V Randrianarison S Brodie J Salstrom TP Rasmussen A Klimke C Marrese Y Marahrens CX Deng J Feunteun DM Livingston 2002 Brca1 supports XIST RNA concentration on the inactive X chromosome Cell 111 3 393 405 S0092867402010528[pii] 12419249 10.1016/S0092-8674(02)01052-8 1:CAS:528:DC%2BD38XovVaku7o%3D (Pubitemid 35341392)
27. M Kriege C Seynaeve H Meijers-Heijboer JM Collee MB Menke-Pluymers CC Bartels MM Tilanus-Linthorst A van den Ouweland B van Geel CT Brekelmans JG Klijn 2008 Distant disease-free interval, site of first relapse and post-relapse survival in brca1- and brca2-associated compared to sporadic breast cancer patients Breast Cancer Res Treat 111 2 303 311 10.1007/s10549-007-9781-7 17952592 10.1007/s10549-007-9781-7
28. EA Rakha JS Reis-Filho IO Ellis 2008 Impact of basal-like breast carcinoma determination for a more specific therapy Pathobiology 75 2 95 103 10.1159/000123847 18544964 10.1159/000123847 (Pubitemid 351820727)
29. AL Richardson ZC Wang A De Nicolo X Lu M Brown A Miron X Liao JD Iglehart DM Livingston S Ganesan 2006 X chromosomal abnormalities in basal-like human breast cancer Cancer Cell 9 2 121 132 10.1016/j.ccr.2006.01.013 16473279 10.1016/j.ccr.2006.01.013 1:CAS:528:DC%2BD28XhvFynsrg%3D (Pubitemid 43202662)
30. BP Schneider EP Winer WD Foulkes J Garber CM Perou A Richardson GW Sledge LA Carey 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 24 8010 8018 10.1158/1078-0432.CCR-08-1208 19088017 10.1158/1078-0432.CCR-08-1208 1:CAS:528:DC%2BD1cXhsV2it73F
31. M Tirkkonen O Johannsson BA Agnarsson H Olsson S Ingvarsson R Karhu M Tanner J Isola RB Barkardottir A Borg OP Kallioniemi 1997 Distinct somatic genetic changes associated with tumor progression in carriers of brca1 and brca2 germ-line mutations Cancer Res 57 7 1222 1227 9102202 1:CAS:528: DyaK2sXit1Kqu7o%3D (Pubitemid 27152540)
32. WD Foulkes JS Brunet IM Stefansson O Straume PO Chappuis LR Begin N Hamel JR Goffin N Wong M Trudel L Kapusta P Porter LA Akslen 2004 The prognostic implication of the basal-like (cyclin e high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of brca1-related breast cancer Cancer Res 64 3 830 835 14871808 10.1158/0008-5472.CAN-03-2970 1:CAS:528: DC%2BD2cXhtFCgtLo%3D (Pubitemid 38176880)
33. N Turner A Tutt A Ashworth 2004 Hallmarks of 'brcaness' in sporadic cancers Nat Rev Cancer 4 10 814 819 10.1038/nrc1457 15510162 10.1038/nrc1457 1:CAS:528:DC%2BD2cXos1ymu7g%3D (Pubitemid 39331153)
34. H Farmer N McCabe CJ Lord AN Tutt DA Johnson TB Richardson M Santarosa KJ Dillon I Hickson C Knights NM Martin SP Jackson GC Smith A Ashworth 2005 Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy Nature 434 7035 917 921 10.1038/nature03445 15829967 10.1038/nature03445 1:CAS:528:DC%2BD2MXjtFOmsrc%3D (Pubitemid 40559006)
35. RD Kennedy JE Quinn PB Mullan PG Johnston DP Harkin 2004 The role of brca1 in the cellular response to chemotherapy J Natl Cancer Inst 96 22 1659 1668 10.1093/jnci/djh312 15547178 10.1093/jnci/djh312 1:CAS:528: DC%2BD2cXhtVSqsrzO (Pubitemid 39585635)
36. EA Rakha IO Ellis 2009 Triple-negative/basal-like breast cancer: review Pathology 41 1 40 47 10.1080/00313020802563510 19089739 10.1080/ 00313020802563510
37. N Turner A Tutt A Ashworth 2005 Targeting the DNA repair defect of brca tumours Curr Opin Pharmacol 5 4 388 393 10.1016/j.coph.2005.03.006 15955736 10.1016/j.coph.2005.03.006 1:CAS:528:DC%2BD2MXlvFKlsLY%3D (Pubitemid 40932041)
38. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson KR Hess J Stec M Ayers P Wagner P Morandi C Fan I Rabiul JS Ross GN Hortobagyi L Pusztai 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 5678 5685 10.1158/1078-0432.CCR- 04-2421 16115903 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
39. S Mabuchi C Kawase DA Altomare K Morishige K Sawada M Hayashi M Tsujimoto M Yamoto AJ Klein-Szanto RJ Schilder M Ohmichi JR Testa T Kimura 2009 Mtor is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary Clin Cancer Res 15 17 5404 5413 10.1158/1078-0432.CCR-09-0365 19690197 10.1158/1078-0432.CCR-09-0365 1:CAS:528:DC%2BD1MXhtVOntrjK
40. S Mabuchi DA Altomare M Cheung L Zhang PI Poulikakos HH Hensley RJ Schilder RF Ozols JR Testa 2007 Rad001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res 13 14 4261 4270 10.1158/1078-0432.CCR-06- 2770 17634556 10.1158/1078-0432.CCR-06-2770 1:CAS:528:DC%2BD2sXnvVChtr4%3D (Pubitemid 47105991)
41. HY Zhang PN Zhang H Sun 2009 Aberration of the pi3k/akt/mtor signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy Eur J Obstet Gynecol Reprod Biol 146 1 81 86 10.1016/j.ejogrb.2009.04.035 19540648 10.1016/j.ejogrb.2009.04.035 1:CAS:528:DC%2BD1MXpvF2ru7w%3D
42. VL Bae-Jump C Zhou JF Boggess PA Gehrig 2009 Synergistic effect of rapamycin and cisplatin in endometrial cancer cells Cancer 115 17 3887 3896 10.1002/cncr.24431 19484784 10.1002/cncr.24431 1:CAS:528:DC%2BD1MXhtFCku73N
43. O Ekshyyan Y Rong X Rong KM Pattani F Abreo G Caldito JK Chang F Ampil J Glass CA Nathan 2009 Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor cci-779 to cisplatin in experimental models of head and neck squamous cell carcinoma Mol Cancer Ther 8 8 2255 2265 10.1158/1535-7163.MCT-08-1184 19625495 10.1158/1535-7163.MCT-08-1184 1:CAS:528:DC%2BD1MXpvFCnu7c%3D
44. LZ Liu XD Zhou G Qian X Shi J Fang BH Jiang 2007 Akt1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70s6k1 pathway Cancer Res 67 13 6325 6332 10.1158/0008-5472.CAN-06-4261 17616691 10.1158/0008-5472.CAN-06-4261 1:CAS:528:DC%2BD2sXnsVyqtL8%3D (Pubitemid 47037515)
45. T Sinnberg K Lasithiotakis H Niessner B Schittek KT Flaherty D Kulms E Maczey M Campos J Gogel C Garbe F Meier 2009 Inhibition of pi3k-akt-mtor signaling sensitizes melanoma cells to cisplatin and temozolomide J Invest Dermatol 129 6 1500 1515 10.1038/jid.2008.379 19078992 10.1038/jid.2008.379 1:CAS:528:DC%2BD1MXlslGitrY%3D
46. KH Tam ZF Yang CK Lau CT Lam RW Pang RT Poon 2009 Inhibition of mtor enhances chemosensitivity in hepatocellular carcinoma Cancer Lett 273 2 201 209 10.1016/j.canlet.2008.08.018 18824293 10.1016/j.canlet.2008.08.018 1:CAS:528:DC%2BD1cXhsV2gtbrJ
47. C Thallinger W Poeppl B Pratscher M Mayerhofer P Valent G Tappeiner C Joukhadar 2007 Cci-779 plus cisplatin is highly effective against human melanoma in a scid mouse xenotranplantation model Pharmacology 79 4 207 213 10.1159/000101008 17377418 10.1159/000101008 1:CAS:528:DC%2BD2sXlvFGktr8%3D (Pubitemid 46848540)
48. I Beuvink A Boulay S Fumagalli F Zilbermann S Ruetz T O'Reilly F Natt J Hall HA Lane G Thomas 2005 The mtor inhibitor rad001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation Cell 120 6 747 759 10.1016/j.cell.2004.12.040 15797377 10.1016/j.cell.2004.12.040 1:CAS:528:DC%2BD2MXjtVOqt7Y%3D (Pubitemid 40568794)
49. M Wangpaichitr C Wu M You MT Kuo L Feun T Lampidis N Savaraj 2008 Inhibition of mtor restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins Eur J Pharmacol 591 1-3 124 127 10.1016/j.ejphar.2008.06.028 18585380 10.1016/j.ejphar.2008.06.028 1:CAS:528:DC%2BD1cXps12lsr4%3D